Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.
Hochmair M, Schenker M, Cobo Dols M, Kim TM, Ozyilkan O, Smagina M, Leonova V, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E.
Hochmair M, et al. Among authors: aggarwal h.
J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420-1. doi: 10.1016/j.jtho.2024.10.012. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 39477187
Free article.